These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 32300026)

  • 1. IQOS is not an acronym: a call to researchers and journals.
    Seidenberg A; Freeman B
    Tob Control; 2021 May; 30(3):356-358. PubMed ID: 32300026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Categorizing IQOS-Related Twitter Discussions.
    Barker JO; Vassey J; Chen-Sankey JC; Allem JP; Cruz TB; Unger JB
    Int J Environ Res Public Health; 2021 Apr; 18(9):. PubMed ID: 33946546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IQOS: examination of Philip Morris International's claim of reduced exposure.
    St Helen G; Jacob Iii P; Nardone N; Benowitz NL
    Tob Control; 2018 Nov; 27(Suppl 1):s30-s36. PubMed ID: 30158205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IQOS labelling will mislead consumers.
    McKelvey K; Popova L; Kim M; Lempert LK; Chaffee BW; Vijayaraghavan M; Ling P; Halpern-Felsher B
    Tob Control; 2018 Nov; 27(Suppl 1):s48-s54. PubMed ID: 30158208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heated tobacco products likely appeal to adolescents and young adults.
    McKelvey K; Popova L; Kim M; Chaffee BW; Vijayaraghavan M; Ling P; Halpern-Felsher B
    Tob Control; 2018 Nov; 27(Suppl 1):s41-s47. PubMed ID: 30352843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Revolution or redux? Assessing IQOS through a precursor product.
    Elias J; Dutra LM; St Helen G; Ling PM
    Tob Control; 2018 Nov; 27(Suppl 1):s102-s110. PubMed ID: 30305324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Marketing IQOS in a dark market.
    Mathers A; Schwartz R; O'Connor S; Fung M; Diemert L
    Tob Control; 2019 Mar; 28(2):237-238. PubMed ID: 29724866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Creating a market for IQOS: analysis of Philip Morris' strategy to introduce heated tobacco products to the Australian consumer market.
    Watts C; Burton S; Freeman B
    Tob Control; 2022 May; 31(3):458-463. PubMed ID: 33191270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of industry data on pulmonary and immunosuppressive effects of IQOS.
    Moazed F; Chun L; Matthay MA; Calfee CS; Gotts J
    Tob Control; 2018 Nov; 27(Suppl 1):s20-s25. PubMed ID: 30158203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Awareness, experience and prevalence of heated tobacco product, IQOS, among young Korean adults.
    Kim J; Yu H; Lee S; Paek YJ
    Tob Control; 2018 Nov; 27(Suppl 1):s74-s77. PubMed ID: 30158210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Free-Base and Total Nicotine, Reactive Oxygen Species, and Carbonyl Emissions From IQOS, a Heated Tobacco Product.
    Salman R; Talih S; El-Hage R; Haddad C; Karaoghlanian N; El-Hellani A; Saliba NA; Shihadeh A
    Nicotine Tob Res; 2019 Aug; 21(9):1285-1288. PubMed ID: 30476301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of IQOS introduction on Philip Morris International cigarette sales in Spain: a Logarithmic Mean Divisa Index decomposition approach.
    Golpe AA; Martín-Álvarez JM; Galiano A; Asensio E
    Gac Sanit; 2022; 36(4):293-300. PubMed ID: 35219532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IQOS point-of-sale marketing strategies in Israel: a pilot study.
    Bar-Zeev Y; Levine H; Rubinstein G; Khateb I; Berg CJ
    Isr J Health Policy Res; 2019 Jan; 8(1):11. PubMed ID: 30642383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PMI's own in vivo clinical data on biomarkers of potential harm in Americans show that IQOS is not detectably different from conventional cigarettes.
    Glantz SA
    Tob Control; 2018 Nov; 27(Suppl 1):s9-s12. PubMed ID: 30131374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Household Surveys in the General Population and Web-Based Surveys in IQOS Users Registered at the Philip Morris International IQOS User Database: Protocols on the Use of Tobacco- and Nicotine-Containing Products in Germany, Italy, and the United Kingdom (Greater London), 2018-2020.
    Sponsiello-Wang Z; Langer P; Prieto L; Dobrynina M; Skiada D; Camille N; Weitkunat R; Lüdicke F
    JMIR Res Protoc; 2019 May; 8(5):e12061. PubMed ID: 31094340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IQOS - a heat-not-burn (HnB) tobacco product - chemical composition and possible impact on oxidative stress and inflammatory response. A systematic review.
    Kopa PN; Pawliczak R
    Toxicol Mech Methods; 2020 Feb; 30(2):81-87. PubMed ID: 31532297
    [No Abstract]   [Full Text] [Related]  

  • 17. IQOS
    Adriaens K; Gucht DV; Baeyens F
    Int J Environ Res Public Health; 2018 Dec; 15(12):. PubMed ID: 30567400
    [No Abstract]   [Full Text] [Related]  

  • 18. FDA's reduced exposure marketing order for IQOS: why it is not a reliable global model.
    Lempert LK; Bialous S; Glantz S
    Tob Control; 2022 Aug; 31(e1):e83-e87. PubMed ID: 33811155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Informing iQOS Regulations in the United States: A Synthesis of What We Know.
    Berg CJ; Bar-Zeev Y; Levine H
    Sage Open; 2020; 10(1):. PubMed ID: 32719733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolving IQOS packaging designs change perceptions of product appeal, uniqueness, quality and safety: a randomised experiment, 2018, USA.
    Lee JGL; Blanchflower TM; O'Brien KF; Averett PE; Cofie LE; Gregory KR
    Tob Control; 2019 Aug; 28(e1):e52-e55. PubMed ID: 31164489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.